Protagonist Therapeutics, Inc. (PTGX) News

Protagonist Therapeutics, Inc. (PTGX): $33.26

-1.45 (-4.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter PTGX News Items

PTGX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PTGX News Highlights

  • For PTGX, its 30 day story count is now at 17.
  • Over the past 20 days, the trend for PTGX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • DRUG, ASH and PV are the most mentioned tickers in articles about PTGX.

Latest PTGX News From Around the Web

Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition which causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting® of t

Yahoo | November 15, 2021

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler.

Yahoo | November 11, 2021

Protagonist Therapeutics Inc. (NASDAQ: PTGX) An Analysis Is What You Need

Protagonist Therapeutics Inc. (NASDAQ:PTGX) traded at $34.64 at close of the session on Monday, 11/08/21, made an upward move of 2.67% on its previous days price. Looking at the stock we see that its previous close was $33.74 and the beta (5Y monthly) reads 1.55 with the days price range being $33.79 $34.99. In Protagonist Therapeutics Inc. (NASDAQ: PTGX) An Analysis Is What You Need Read More »

Stocks Register | November 9, 2021

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lessened by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 391,943 shares of the companys stock after selling 22,191 shares during the quarter. Goldman Sachs Group Inc. owned 0.82% of Protagonist []

Transcript Daily | November 9, 2021

Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $56.75

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has earned an average recommendation of Buy from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that []

Dakota Financial News | November 9, 2021

Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

The Motley Fool | November 8, 2021

Protagonist Therapeutics, Inc. Forecasted to Earn FY2021 Earnings of ($2.67) Per Share (NASDAQ:PTGX)

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock analysts at Jefferies Financial Group reduced their FY2021 earnings per share (EPS) estimates for Protagonist Therapeutics in a research report issued on Wednesday, November 3rd. Jefferies Financial Group analyst C. Howerton now forecasts that the company will earn ($2.67) per share for the year, down from their previous forecast []

Transcript Daily | November 8, 2021

Protagonist Therapeutics (NASDAQ:PTGX) Announces Earnings Results, Misses Expectations By $0.03 EPS

Protagonist Therapeutics (NASDAQ:PTGX) posted its quarterly earnings data on Wednesday. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.03), MarketWatch Earnings reports. Protagonist Therapeutics had a negative net margin of 299.39% and a negative return on equity of 30.58%. Shares of NASDAQ PTGX traded down $0.12 during mid-day […]

Dakota Financial News | November 6, 2021

Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) have been selected for oral presentations at the American Society of Hematology (ASH) 2021 Annual Meeting taking place December 11-14, 2021. An additional three abstracts on rusfertide in PV and hereditary hemochromatosis (HH) have been accepted as poster presentations at ASH.

Yahoo | November 4, 2021

Zacks: Brokerages Anticipate Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Will Announce Quarterly Sales of $3.43 Million

Equities research analysts expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will announce $3.43 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Protagonist Therapeutics earnings, with estimates ranging from $2.30 million to $5.00 million. Protagonist Therapeutics posted sales of $13.11 million during the same quarter last year, which []

Transcript Daily | November 3, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.58 seconds.